-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Benzinga·03/26/2026 12:08:59
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.